Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

This trial compares two radiation approaches for people with inoperable, locally advanced non-small cell lung cancer (NSCLC). One approach delivers radiation in fewer, larger daily doses (hypofractionated), while the other uses the standard smaller daily doses. Both are combined with chemotherapy, and may be followed by immunotherapy. **You may be eligible if...** - You are 18 to 75 years old - You have been diagnosed with stage III non-small cell lung cancer that cannot be surgically removed - Your tumor does not have EGFR mutations or ALK rearrangements (common genetic changes that affect treatment) - You have not received prior systemic treatment, OR you received induction chemotherapy with or without immunotherapy - Your overall health is reasonably good and your expected survival is at least 12 weeks - You are willing to provide a tumor tissue sample **You may NOT be eligible if...** - You have small cell lung cancer or another subtype not classified as NSCLC - Your tumor has EGFR or ALK gene changes - Your general health is too poor to tolerate treatment - You have active autoimmune disease or serious heart/lung conditions Talk to your doctor to see if this trial is right for you.